ArticleFrontiers in immunology2026
Ratanasampil alleviates cognitive impairment in mice induced by chronic hypoxia by modulating inflammatory responses.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic hypoxia at high altitudes contributes to cognitive decline, but effective therapies are lacking. The traditional Tibetan medicine Ratanasampil (RNSP) has neuroprotective properties, yet its effects on hypoxia-induced cognitive impairment and associated inflammation remain unknown. Methods: Aged C57BL/6J mice were exposed to chronic hypobaric hypoxia with or without RNSP pretreatment (7 mg/kg/d, 7 days plus concomitant administration). Cognitive function was assessed by Morris water maze and open field tests. Neuroinflammation, amyloid-β (Aβ) pathology, peripheral immune cell profiles (spleen and blood), and serum cytokine levels were analyzed. Results: RNSP treatment significantly improved spatial learning and memory deficits and reduced anxiety-like behavior induced by chronic hypoxia. In the brain, RNSP lowered the expression of IL-1β, IL-6, and TNF-α in the hippocampus and cortex. In peripheral tissues, RNSP reversed hypoxia-induced reductions in splenic and circulating CD3 Conclusion: RNSP alleviates chronic hypoxia-induced cognitive impairment through dual anti-inflammatory actions on both the central nervous system and peripheral immune compartments. These findings support RNSP as a promising therapeutic candidate for high-altitude cognitive decline and possibly other inflammation-related neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.